Searchable abstracts of presentations at key conferences in endocrinology

ea0024s27 | Endocrine Nurse session | BSPED2010

RCN CYP specialist care forum: endocrine community update

Martin L

Background: 2003 saw the formation of a special interest group within the Royal College of Nursing (RCN) for the growing number of paediatric nurses working within the field of endocrinology. While this group has strong links with the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the British Endocrine Society (BES), it was felt these societies were strongly medical and that a unified voice for paediatric endocrinology nurses would be a useful addition.</...

ea0017p36 | (1) | BSPED2008

Outcomes of screening protocol in children at risk of Von-Hippel Lindau syndrome

Prasad R , Martin L , Savage M , Storr H , Johnston L

Von-Hippel Lindau syndrome (VHL) is a familial disorder presenting in children with a range of different neoplasia. A paediatric screening protocol was published in 2000 and has now been applied to patients in our centre. Screening for VHL is multi-disciplinary involving clinical, biochemical, and radiological investigations.Methods: Data was collected between 2000 and 2007 in 14 children on compliance with screening and identification of pathological le...

ea0049ep150 | Endocrine tumours and neoplasia | ECE2017

Small pancreatic neuroendocrine incidentalomas: an observational prospective study

Villabona C , Busquets J , Martin L San , Planas A , Pelaez N , Fabregat J , Teule A , Peiro I

Background: Diagnosis of small pancreatic neuroendocrine incidentalomas (PNETs-I) is increasing during last years and often their management remains unclear.Objective: To describe our experience with patients with PNETs-I in our institution.Methods: Since March 2000, patients with non functioning PNETs-I ≤30 mm were evaluated in our center, prospectively. A descriptive analysis of all patients and a comparative study between ...

ea0029p931 | Female Reproduction | ICEECE2012

Conformational control of P450aromatase by lipid membrane interactions and protein associations

Martin L. , Praporski S. , Rodgers R. , Corbin C. , Conley A. , Mizrachi D.

Cytochrome P450 aromatase is a membrane bound enzyme that synthesises estrogens. This reaction involves electron delivery from NADPH via cytochrome P450 reductase (CPR). Little is known as to how the P450arom performs the aromatase reaction or how it associates with CPR in the endoplasmic reticulum (ER). In humans, there is only one P450arom, however pigs have three isozymes. The catalytic efficiency of one of these, the porcine gonadal P450arom, is much lower than the human a...

ea0086op6.3 | Endocrine Cancer and Late Effects | SFEBES2022

Knockout mouse embryonic fibroblasts reveal a physiological role for the proto-oncogene PBF in cell adhesion and motility

Kocbiyik Merve , Manivannan Selvambigai , Brookes Katie , Zha Ling , Nieto Hannah R , Read Martin L , McCabe Christopher J , Smith Vicki E

The proto-oncogene pituitary tumor-transforming gene-binding factor (PBF) is upregulated in multiple tumours including thyroid cancer. PBF overexpression mediates tumorigenic processes such as cell motility and accelerates thyroid cancer cell invasion. We have recently shown that both PBF phosphorylation at tyrosine 174 (Y174) and PBF endocytosis are required for PBF-stimulated thyroid and breast cancer cell migration and invasion. This prompted further investigation into a ph...

ea0049gp241 | Thyroid Cancer &amp; Thyroid Case Reports | ECE2017

Thyroid-related adverse events in patients treated with Nivolumab

Peiro I , Martin L San , Simo-Servat A , Otero J , Ruffinelli JC , Nadal E , Iglesias P , Diez JJ , Villabona C

Introduction: Nivolumab is an antibody that binds to and blocks the activation of programmed-death-receptor 1(PD-1), promoting the activation of T-cells against tumor cells. Thyroid dysfunction (TD) is one of the most common immuno-related adverse events, with incidence up to 10% in patients treated with PD-1/PD-L1 blockade.Objective: To report our experience of Nivolumab-TD in patients with advanced cancer.Methods: All patients di...

ea0034p191 | Neoplasia, cancer and late effects | SFEBES2014

ATR kinase function is modulated by the proto-oncogene PBF

Fan Hui , Gagliano Teresa , Read Martin L , Franklyn Jayne A , Boelaert Kristien , Turnell Andrew S , McCabe Christofer J

Disruption of DNA damage response pathways results in an accumulation of genetic mutations, gene amplifications and chromosome alterations, which are key initiating factors in cellular transformation and oncogenesis. PBF is a multifunctional proto-oncogene which is overexpressed in thyroid, pituitary and breast cancers, with roles in cell transformation, invasion and transporter regulation. Recently, we reported that targeted transgenic expression of PBF promotes genetic insta...

ea0017p56 | (1) | BSPED2008

Implementing the RCN competency framework for paediatric endocrine nurses

Davies K , P Musson , Casey A , Walker J , Whitehead A , Martin L , Langham S , McNeill E , Reid J , Davies JH

Background: There have been a number of drivers that have led nurses to take on extended roles that have been traditionally been the domain of doctors. Competency frameworks for specialist nurses have been developed in other paediatric specialities, such as diabetes, oncology and epilepsy. However, this has not been established for paediatric endocrine nurses.Aim: To establish a competency framework for paediatric endocrine nurse specialists.<p class...

ea0077oc2.4 | Endocrine Cancer and Late Effects | SFEBES2021

PBF phosphorylation regulates cell motility of thyroid and breast cancer cells

Kocbiyik Merve , Alshahrani Mohammed , Poole Vikki L , Jeyanathan Sakaorna , Thornton Caitlin , Zha Ling , Brookes Katie , Nieto Hannah , Read Martin L , McCabe Chris J , Smith Vicki E

The proto-oncogene pituitary tumor transforming gene binding factor (PTTG1IP/PBF) is overexpressed in multiple tumours and associated with tumour progression. One of the tumourigenic processes that PBF can mediate is cell motility. PBF can induce cell invasion in both thyroid and breast cancer cell lines. However, in contrast to wild-type (WT) PBF, the Y174A PBF mutant was not able to induce the invasiveness of thyroid or breast cancer cells. The Y174 residue is highly phospho...